A Multicenter, Open-label, Prospective Study of Ixazomib, Lenalidomide, and Ixazomib in Combination With Lenalidomide for Maintenance Therapy in Patients With Newly Diagnosed Multiple Myeloma
Latest Information Update: 05 Aug 2024
At a glance
- Drugs Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
Most Recent Events
- 01 Aug 2024 Status changed from active, no longer recruiting to completed.
- 15 Jun 2023 Primary endpoint (overall survival) has not been met according to results presented at the 28th Congress of the European Haematology Association.
- 15 Jun 2023 Primary endpoint (progression-free survival) has not been met according to results presented at the 28th Congress of the European Haematology Association.